Dear Editor,

Since the outbreak of a novel coronavirus disease (COVID-19) in late 2019, it has spread rapidly and developed into a global pandemic. As of August 12, 2020, more than 215 countries and territories around the world have reported more than 20.5 million confirmed COVID-19 cases with over 745,693 deaths (<https://www.worldometers.info/coronavirus/#countries>). Such harsh conditions urged scientists across the world to gear up to develop vaccines and antiviral drugs against COVID-19, which also lead to massive requirement for experimental animals.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of COVID-19. It has been demonstrated that SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) as cellular receptor for entry into target cells. Mouse model is the most commonly used animal model for studying human diseases. However, SARS-CoV-2 fails to invade and replicate in this traditional animal model due to the structural differences in mouse ACE2 (mACE2) compared with human ACE2 (hACE2),^[@CR1]^ which has become the major hurdle for COVID-19 study. Currently, several strategies have been developed to overcome this receptor incompatibility by: (i) generating transgenic mice bearing hACE2 receptor,^[@CR2]--[@CR4]^ (ii) establishing adenovirus hACE2 mouse model with recombinant adenovirus expressing hACE2,^[@CR5]^ and (iii) adapting the SARS-CoV-2 by serial passages in the respiratory tract of mice.^[@CR6]--[@CR8]^

In this study, we used an alternative strategy to generate a SARS-CoV-2-sensitive mouse model by exogenous delivery of hACE2 with Venezuelan equine encephalitis replicon particles (VEEV-VRP-hACE2) ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S1a](#MOESM1){ref-type="media"}). VEEV is a positive sense, single-stranded RNA virus which belongs to the genus *Alphavirus*, family *Togaviridae*. Alphavirus replicon particles (VRPs), including VEEV-VRPs, represent efficient vectors for gene delivery and have been applied to studies of vaccine development, gene therapy and cell transduction. They contain self-replicating RNA-encoding viral replicase proteins (nsP1-nsP4) and express the gene of interest in place of viral structural protein genes.^[@CR9]^ By providing viral structural proteins in trans, the replicon RNA is packaged into VEEV-VRPs for in vitro and in vivo gene delivery.^[@CR10]^ Due to their intrinsic biological properties, VEEV-VRPs offer several advantages with a broad range of susceptible host cells, high expression level of cytoplasmic proteins and easy manipulation of recombinant RNA molecules using cDNA clones.^[@CR10],[@CR11]^

Here, Venezuelan equine encephalitis virus (VEEV) replicon expressing hACE2 with a C-terminal S-tag was packaged into VRPs using the helper RNAs encoding VEEV capsid and envelope proteins to produce VEEV-VRP-hACE2 ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S1](#MOESM1){ref-type="media"}). MLE-12 cells (mouse lung type II epithelial cell line) were used to evaluate the availability of VEEV-VRP-hACE2 for SARS-CoV-2-sensitive cells establishment. After confirming hACE2 expression in MLE-12 cells transduced with VEEV-VRP-hACE2 (VRP-hACE2) through indirect immunofluorescence assay (IFA) (Fig. [1a](#Fig1){ref-type="fig"}) and western blotting (Fig. [1b](#Fig1){ref-type="fig"}), MLE-12 cells were administered with VEEV-VRP-hACE2 at 12 h prior to SARS-CoV-2 (WIV04)^[@CR1]^ infection. The SARS-CoV-2 NP-specific IFA-positive cells were only observed in VEEV-VRP-hACE2-transduced MLE-12 cells but not in the DMEM-treated cells (Fig. [1c](#Fig1){ref-type="fig"}). Similar results were obtained using BHK-21 cells (Fig. [1c](#Fig1){ref-type="fig"}). These results demonstrated that VEEV-VRP-hACE2 could efficiently deliver hACE2 in vitro and convert nonpermissive cells into SARS-CoV-2-permissive cells.Fig. 1Development of mouse model for SARS-CoV-2 infection.**a**, **b** Expression of hACE2 was analyzed using IFA (**a**) and western blot assay (**b**) in MLE-12 cells transduced with VEEV-VRP-hACE2. **c** Transduction with VEEV-VRP-hACE2 converted nonpermissive MLE-12 cells and BHK-21 cells into SARS-CoV-2 permissive cells. **d**, **e** Viral RNA loads of lung tissues in VEEV-VRP-hACE2-transduced BALB/c (**d**) and C57BL/6 mice (**e**) after infection with SARS-CoV-2. **f** Viral RNA loads of different tissues in the BABL/c mice transduced with VEEV-VRP-hACE2 followed by SARS-CoV-2 infection. **g** White blood cells analysis in the peripheral blood collected from each group of BALB/c mice. **h** SARS-CoV-2 antigen detection in the lung tissues of BALB/c mice transduced with VEEV-VRP-hACE2 and infected with SARS-CoV-2 using anti-NP antibody. **i** H&E staining of lung samples from infected BALB/c mice at 4 dpi. **j** Viral RNA loads of lungs in BALB/c mice inoculated with CB6 at 2 days post challenge with SARS-CoV-2. **k** Viral RNA loads of lungs in BALB/c mice twice immunized with inactivated SARS-CoV-2 vaccines at 2 days post challenge with SARS-CoV-2. Data were expressed as means ± SD, Student's *t* test was used to analyze the differences between two groups. \*\**P* \< 0.01, \*\*\**P* \< 0.001. Scale bars, 50 μm (**a**, **c**), 100 μm (**h**, **i** left), 50 μm (**i** right).

We then tested whether VEEV-VRP-hACE2 could in vivo deliver hACE2 to the respiratory tract of mouse and render susceptibility to SARS-CoV-2 infection. Both BALB/c and C57BL/6 mice around 6- to 8-week-old were first administered with 10^6^ IU VEEV-VRP-hACE2 or DMEM (negative control) in a volume of 80 μL DMEM through intranasal route. After 24 h, mice from different groups were inoculated intranasally with 10^5^ PFU SARS-CoV-2, and then were monitored and weighted daily for 14 days. No obvious clinical symptoms and body weight loss were observed for mice in each group ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S2a](#MOESM1){ref-type="media"}). The viral replication dynamics in the lungs of mice were determined through quantification of viral genomic RNAs. As shown in Fig. [1d, e](#Fig1){ref-type="fig"}, viral RNAs remained at a steady high level (10^6^--10^7^ copies/g) in both BALB/c and C57BL/6 mice transduced with VEEV-VRP-hACE2 from day 1 to day 5 post infection and decreased to background levels (10^4^ copies/g) on day 9 in transduced BALB/c mice ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S2b](#MOESM1){ref-type="media"}). In contrast, the continuous decline in viral RNA levels was observed in DMEM-treated mice over the whole experimental period (Fig. [1d, e](#Fig1){ref-type="fig"}). In VEEV-VRP-hACE2-transduced mice, viral RNAs were not detected in other organs such as heart, liver, spleen, kidney, brain and small intestine except for lung (Fig. [1f](#Fig1){ref-type="fig"}). NP antigen of SARS-CoV-2 was also observed in the lungs through IFA (Fig. [1h](#Fig1){ref-type="fig"}). Similar to the results reported in SARS-CoV-2-infected transgenic mice,^[@CR3]^ VEEV-VRP-hACE2-transduced, SARS-CoV-2-infected mice (VRP-hACE2+SARS-CoV-2) had a higher neutrophil-to-lymphocyte ratio in the peripheral blood at 2 days post infection (dpi) compared with the mice infected with SARS-CoV-2 (SARS-CoV-2) or transduced with VEEV-VRP-hACE2 only (VRP-hACE2) (Fig. [1g](#Fig1){ref-type="fig"}). Moreover, SARS-CoV-2 infection induced the production of viral-specific IgG antibodies in the sera of VEEV-VRP-hACE2-transduced mice, as demonstrated by IFA at 21 dpi, in contrast to the negative IFA signals observed in SARS-CoV-2 only- and VEEV-VRP-hACE2 only-treated mice ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S2c](#MOESM1){ref-type="media"}).

To characterize the pathological features caused by SARS-CoV-2 infection in VEEV-VRP-hACE2-transduced mice, histopathological analysis of lung sections from infected mice were performed (Fig. [1i](#Fig1){ref-type="fig"}). Hematoxylin-eosin (H&E) staining showed that following SARS-CoV-2 infection, hACE2-transduced mice developed interstitial pneumonia (Fig. [1i](#Fig1){ref-type="fig"}) characterized with large area of alveolar septal thickening, part of alveoli atrophy (black arrow), large number of inflammatory cell infiltration around blood vessels and the bronchus (yellow arrow), and a small amount of epithelia/epithelioid cells detached from the bronchus (red arrow). In contrast, only small areas of alveolar septal thickening were observed in the lungs of mock-treated mice infected with SARS-CoV-2 or mice only transduced with VEEV-VRP-hACE2. These results suggested that VEEV-VRP-hACE2-transduced mice could support SARS-CoV-2 replication and develop similar pulmonary pathology to that observed in COVID-19 patients after SARS-CoV-2 infection.

To further evaluate the availability of this mouse model for COVID-19 study, a human neutralizing antibody CB6 that is a potential agent for COVID-19^[@CR12]^ and an inactivated vaccine candidate that had entered clinical trials were chosen to examine their protective effects against SARS-CoV-2 infection using this mouse model. For CB6 protective assay, viral RNAs in the lungs of VEEV-VRP-hACE2-transduced mice were quantified at 3 d after SARS-CoV-2 infection. Consistent with previous study,^[@CR12]^ CB6 exhibited strong protective effects against SARS-CoV-2 infection as the viral RNAs of CB6 mAb treated group were more than twenty times lower than those of mock-treated group (Fig. [1j](#Fig1){ref-type="fig"}). Histopathological analysis of lung sections provided further evidence that in contrast to typical pulmonary features of COVID-19 lung disease displayed by mock-treated mice, no lesions were observed in antibody-treated group ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S2d](#MOESM1){ref-type="media"}). For vaccine protection assay, BALB/c mice were immunized twice with 5 μg inactivated vaccine through the intraperitoneal route at an interval of 14 days. The mice mock immunized with PBS were used as control. Apparent seroconversion was observed in vaccine-immunized mice at 14 days post boosting vaccination through ELISA and PRNT assays, while none of the mock-immunized mice seroconverted ([Supplementary information](#MOESM1){ref-type="media"}, Fig. [S2c](#MOESM1){ref-type="media"}). Following VEEV-VRP-hACE2 transduction, both groups of mice were challenged with 10^5^ PFU SARS-CoV-2 via intranasal route. The inactivated vaccine significantly protected mice from SARS-CoV-2 infection, as dramatically decreased RNA copies were detected in the vaccine-immunized mice compared with those in the mock-immunized mice (Fig. [1k](#Fig1){ref-type="fig"}).

Overall, these results show that the VEEV-VRP-hACE2-transduced mouse model can be rapidly established without any genetic manipulation (knock-out/in), and the productive viral replication and visible histopathology in transduced mice that mimic clinical COVID-19 illness allow us to test potential antiviral agents and vaccines using this model.
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